BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - BioRestorative Therapies, Inc. reported its third quarter financial results for 2025, highlighting strong clinical development and business momentum, with a focus on near- and mid-term value opportunities [2][9] Corporate Developments - The company anticipates a Type B meeting with the FDA regarding an accelerated Biologics License Application (BLA) for its BRTX-100 program aimed at treating chronic lumbar disc disease [4] - BioRestorative achieved a significant intellectual property milestone with the Japanese Patent Office granting a Notice of Allowance for its ThermoStem platform, which focuses on treating obesity and metabolic disorders [5] - The appointment of Crystal Romano as Head of Global Commercial Operations aims to accelerate growth in the cell-based product portfolio [6][8] Financial Highlights - For Q3 2025, the company reported revenues of approximately $11,800, a decrease from $233,600 in Q3 2024, primarily due to the timing of orders for BioCosmeceutical sales [9] - The loss from operations for Q3 2025 was $3.7 million, compared to $2.3 million in the same period of 2024, with a net loss of $3.0 million or $0.33 per share [10] - The company ended Q3 2025 with cash and equivalents of $4.5 million, excluding approximately $1.085 million from a recent financing [11] Business Strategy - The company is focused on executing its near-term revenue strategy within the BioCosmeceutical platform while advancing clinical stage programs, which represent multi-billion dollar market opportunities [2] - BioRestorative is developing cell-based therapies targeting obesity and metabolic disorders, utilizing brown adipose-derived stem cells [14][15] - The company operates a commercial BioCosmeceutical platform, with plans to expand its offerings to include a broader range of cell-based aesthetic products [16]